Immunoglobulin (Pathogenic autoantibody) (Ig (autoantibody) (if abbreviation needed; more specifically, IgG or IgM autoantibody when context requires))

Immunoglobulins, also known as antibodies, are glycoproteins produced by plasma cells and represent the effector molecules of the humoral immune response[3][5]. Pathogenic autoantibodies are a subset that aberrantly recognize and bind self-antigens, leading to tissue injury and the pathogenesis of various autoimmune diseases[1][2]. Autoantibodies can be of various immunoglobulin classes (most commonly IgG and less frequently IgM), and their pathogenic potential comes from direct cell targeting, complement activation, immune complex formation, and triggering of inflammatory pathways[2]. Therapies targeting these autoantibodies include immune suppression, antibody removal, and B cell–modulating drugs[1]. Notably, "immunoglobulins/pathogenic autoantibody neutralization/modulation" is not a single molecule or protein, but a general target class or therapeutic strategy. Therefore, while immunoglobulin molecules themselves are well-defined, the phrase as a target refers to the broad concept of neutralizing or modulating pathogenic autoantibodies in disease, which may lack the specificity required for canonical drug target lists. The query target is imprecise; it describes a therapeutic approach or target class ("neutralization/modulation of pathogenic autoantibodies") rather than a molecular target like a specific receptor or enzyme. There is no single molecule named "Immunoglobulins / Pathogenic autoantibody neutralization/modulation." This should be flagged as is_incorrect: true due to lack of specificity and improper target definition for structured target databases. Specificity should be improved by naming a particular autoantibody (e.g., "anti-dsDNA IgG") or a specific receptor (e.g., neonatal Fc receptor) if mechanistic granularity is needed.

Other names

Antibody (autoantibody)AutoantibodyPathogenic autoantibody

Neutralization of autoantibodies Removal or reduction of pathogenic antibodies B cell depletion or modulation Fc receptor blockade